Watch PVCT. Know when insiders buy.
One email the day a filing lands. Free.
PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
0.05
+0.00 +0.00%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $23.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$4.7MNET CASH —52W 0.04 – 0.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$939K | −$983K | — | 0.00 | −$358K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$1.2M | −$1.3M | — | 0.00 | −$358K | — | — | May 14 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$1.1M | −$1.2M | — | 0.00 | −$870K | — | — | Mar 26 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$1.3M | −$1.3M | — | 0.00 | −$840K | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $57K | −77.5% | — | −$1.8M | −$1.8M | — | 0.00 | −$523K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | $279K | +17.0% | — | −$1.1M | −$1.1M | — | 0.00 | −$1.1M | — | — | May 14 |
| Q4 2024 · Dec 31derived | $14K | −88.2% | — | −$2.3M | −$2.4M | — | 0.00 | −$912K | — | — | Mar 26 |
| Q3 2024 · Sep 30 | $110K | +57.4% | — | −$956K | −$1M | — | 0.00 | −$565K | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $255K | — | — | −$795K | −$847K | — | 0.00 | −$763K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | $238K | — | — | −$447K | −$504K | — | 0.00 | −$1M | — | — | May 14 |
| Q4 2023 · Dec 31derived | $121K | — | — | −$605K | −$663K | — | 0.00 | −$561K | — | — | Mar 28 |
| Q3 2023 · Sep 30 | $70K | — | — | −$714K | −$776K | — | 0.00 | −$769K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $336K | — | −$5.3M | −$5.4M | -1615.8% | -0.01 | −$3.3M | — | — | — | — |
| FY2024 · to Dec 31 | $617K | — | −$4.5M | −$4.7M | -766.9% | -0.01 | −$3.3M | — | — | — | — |
| FY2023 · to Dec 31 | $558K | — | −$2.9M | −$3.1M | -556.2% | -0.01 | −$2.6M | — | — | — | — |
| FY2022 · to Dec 31 | $989K | — | −$3.4M | −$3.6M | -359.4% | -0.01 | −$3M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$4.7M | −$5.5M | — | -0.01 | −$1M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$5M | −$6.7M | — | -0.02 | −$4.1M | — | — | — | — |
Every number comes from PROVECTUS BIOPHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.